INTU vs PFE: Which Is the Better Buy?
Side-by-side comparison of Intuit Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Intuit Inc. · Technology
$277.13
+25.3% upside to fair value
Med Conviction
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
INTU has more upside to fair value
(+25.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTU |
PFE |
| Current Price |
$277.13 |
$27.64 |
| Fair Value Estimate |
$347.25 |
$30.94 |
| Upside to Fair Value |
+25.3%
|
+12.0%
|
| Market Cap |
$75.8B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
11.0x
|
17.4x
|
| Price / Sales |
3.5x
|
2.5x
|
| Price / FCF |
8.8x
|
14.3x
|
| Revenue Growth YoY |
+13.7%
|
+2.6%
|
| Gross Margin |
80.9%
|
71.3%
|
| Operating Margin |
28.8%
|
25.1%
|
| Return on Equity |
23.4%
|
4.9%
|
| Dividend Yield |
1.73% |
6.22% |
| FCF Yield |
11.43%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Intuit is a financial management software platform serving small and mid-market businesses through QuickBooks, consumers through TurboTax, and consumers through Credit Karma, with a professional tax segment in Lacerte, ProSeries and ProConnect. The business quality is high on fundamentals: TTM gross margin of 80.9%, TTM operating margin of 28.8%, TTM net margin of 21.3%, ROE of 23.4%, and free ca…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
INTU |
PFE |
| Zone Low |
$260.44 |
$23.21 |
| Zone High |
$295.16 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|